Drug Information
| Drug General Information | Top | |||
|---|---|---|---|---|
| Drug ID |
D05PKT
|
|||
| Former ID |
DNC011112
|
|||
| Drug Name |
4-[4-(6-methoxynaphthalen-2-yl)benzyl]pyridine
|
|||
| Synonyms |
CHEMBL1214738; 4-[4-(6-methoxynaphthalen-2-yl)benzyl]pyridine; SCHEMBL18770313
Click to Show/Hide
|
|||
| Drug Type |
Small molecular drug
|
|||
| Indication | Discovery agent [ICD-11: N.A.] | Investigative | [1] | |
| Structure |
 |
Download2D MOL |
||
| Formula |
C23H19NO
|
|||
| Canonical SMILES |
COC1=CC2=C(C=C1)C=C(C=C2)C3=CC=C(C=C3)CC4=CC=NC=C4
|
|||
| InChI |
1S/C23H19NO/c1-25-23-9-8-21-15-20(6-7-22(21)16-23)19-4-2-17(3-5-19)14-18-10-12-24-13-11-18/h2-13,15-16H,14H2,1H3
|
|||
| InChIKey |
XDUUJWUQYXFHEK-UHFFFAOYSA-N
|
|||
| PubChem Compound ID | ||||
| Target and Pathway | Top | |||
|---|---|---|---|---|
| Target(s) | Steroid 17-alpha-monooxygenase (S17AH) | Target Info | Inhibitor | [1] |
| BioCyc | Superpathway of steroid hormone biosynthesis | |||
| Glucocorticoid biosynthesis | ||||
| Androgen biosynthesis | ||||
| KEGG Pathway | Steroid hormone biosynthesis | |||
| Metabolic pathways | ||||
| Ovarian steroidogenesis | ||||
| Prolactin signaling pathway | ||||
| Pathwhiz Pathway | Androgen and Estrogen Metabolism | |||
| Steroidogenesis | ||||
| Reactome | Androgen biosynthesis | |||
| Glucocorticoid biosynthesis | ||||
| Endogenous sterols | ||||
| WikiPathways | Metapathway biotransformation | |||
| Steroid Biosynthesis | ||||
| Oxidation by Cytochrome P450 | ||||
| Metabolism of steroid hormones and vitamin D | ||||
| Glucocorticoid & Mineralcorticoid Metabolism | ||||
| Prostate Cancer | ||||
| Phase 1 - Functionalization of compounds | ||||
| References | Top | |||
|---|---|---|---|---|
| REF 1 | Replacement of imidazolyl by pyridyl in biphenylmethylenes results in selective CYP17 and dual CYP17/CYP11B1 inhibitors for the treatment of prosta... J Med Chem. 2010 Aug 12;53(15):5749-58. | |||
If You Find Any Error in Data or Bug in Web Service, Please Kindly Report It to Dr. Zhou and Dr. Zhang.